#AACR23 (Photo: Nicole DeFeudis for Endpoints News)
April 20, 2023 04:55 AM EDT
R&D

AACR roundup: Merus eyes ac­cel­er­at­ed ap­proval; Im­muneer­ing ac­cel­er­ates RAS drug

Nicole DeFeudis

Editor

Merus of­fered an in­ter­im look at an on­go­ing Phase I/II tri­al for its bis­pe­cif­ic an­ti­body petosem­tam­ab on Mon­day, show­ing an over­all …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times